Current Report Filing (8-k)
2020年1月18日 - 12:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 13, 2020
ACRO BIOMEDICAL CO., LTD.
|
(Exact name of registrant as specified in Charter)
|
Nevada
|
|
333-207765
|
|
47-1950356
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File No.)
|
|
(IRS Employee Identification No.)
|
12175 Visionary Way, Suite 1160; Fishers, Indiana 46038
(Address of Principal Executive Offices)
(317) 286-6788
(Registrant’s Telephone number)
Copies to:
Asher S. Levitsky PC
Ellenoff Grossman & Schole LLP
1345 Avenue of the Americas, Suite 1100
New York, New York 10105
Phone: (646) 895-7152
Fax: (212) 370-7889
E-mail: alevitsky@egsllp.com
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On January 13, 2020, the sole director of the Company determined to change the fiscal year of the Company from the year ending September 30 to the calendar year, effective with the year ended December 31, 2019. The change of fiscal year will be reflected in a Form 10-K for the year ended December 31, 2019.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 17, 2020
|
ACRO BIOMEDICAL CO., LTD.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Pao-Chi Chu
|
|
|
|
Pao-Chi Chu
|
|
|
|
Chief Executive Officer
|
|
Arco Biomedical (CE) (USOTC:ACBM)
過去 株価チャート
から 11 2024 まで 12 2024
Arco Biomedical (CE) (USOTC:ACBM)
過去 株価チャート
から 12 2023 まで 12 2024
Real-Time news about Arco Biomedical Company Ltd (CE) (その他OTC): 0 recent articles
その他のAcro Biomedical Co., Ltd.ニュース記事